Germany passes law on stem cell research
This article was originally published in Clinica
Executive Summary
The decision by the German lower house (Bundestag) last week to allow the restricted import of embryonic stem cells for research purposes has been welcomed by the biotech industry. The move means that MPs have now voted into law the proposals debated in January by a majority of 360 for to 190 compared with 340 for to 265 against during the previous debate (see Clinica No 994, p 5). Three proposed amendments to the law, aimed at either introducing stricter or more relaxed regulations, were defeated.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.